Fueling innovation with accessible mRNA products

The nucleic acid therapeutics industry is experiencing unprecedented growth, driven by the success of mRNA-based vaccines and the promise of RNA-based therapies for a wide range of diseases. As researchers and manufacturers work to develop these transformative treatments and scale up production, the demand for reliable, high-quality tools and reagents has never been greater. With a 25-year legacy as a leader in nucleic acid product development and manufacturing, TriLink Biotechnologies is dedicated to advancing innovation in the field of mRNA therapeutics.

Fueling mRNA therapeutic innovation together

Recognising the need to expand and streamline access to essential nucleic acid products and services, TriLink has announced an exciting new partnership with VWR, a leading global supplier of life sciences solutions. This collaboration ensures that TriLink’s most sought-after products are more readily available to customers across Europe. “This partnership marks an important step in expanding access to our cutting-edge nucleic acid technologies across Europe,” said Becky Buzzeo, Chief Commercial Officer at TriLink. “By collaborating with a trusted distributor like VWR, we can better serve the region’s growing demand for innovative solutions and support the advancement of life-changing therapeutic research.”

Essential tools and solutions made accessible

By leveraging VWR’s extensive distribution network, the partnership simplifies ordering processes, reduces lead times, and accelerates development timelines for researchers and manufacturers in the region. This strategic collaboration underscores companies’ commitment to supporting innovation in both nucleic acid therapeutics and vaccines.

Through this partnership, customers in Europe have expanded access to TriLink’s full catalogue of industry-leading nucleic acid technologies, including:

• CleanCap™ technology, a co-transcriptional mRNA cap analog that streamlines the capping process and overcomes limitations of legacy capping methods
• An extensive portfolio of predesigned mRNAs available for shipping within 36 hours of ordering
• Over 150 modified and unmodified nucleotides available as both catalogue and custom options
• High-performance IVT enzymes, including CleanScribe™ technology, for seamless integration into mRNA synthesis processes

These offerings can all be adapted for Research Use Only (RUO) or manufactured at GMP grade, providing phase-appropriate solutions for early-phase discovery research and commercial manufacturing alike.

Supporting the future of nucleic acid therapeutics

This enhanced accessibility to TriLink’s industry-leading solutions comes at a critical time when the pace of innovation in nucleic acid therapeutics continues to accelerate. By partnering with VWR, TriLink Biotechnologies is not only addressing logistical challenges but also empowering scientists and manufacturers to bring groundbreaking therapies to market more efficiently. As the industry continues to advance, collaborations like this will play a crucial role in supporting its growth and ensuring the timely delivery of groundbreaking solutions to patients worldwide.

To learn more about the partnership and explore TriLink’s full portfolio of tools, visit TriLink Biotechnologies.